Clinical trials
Breast Cancer Triple Negative clinical trials
Below are recruiting breast cancer triple negative clinical trials, each written for real people, not researchers. We’re tracking 431 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05420467RecruitingPhase 4
Trial of add-on breast cancer treatment after surgery
This Phase 4 study tests an additional (adjuvant) treatment for breast cancer after surgery and standard follow-up care. It may help lower the chance the cancer comes back, but you must match specific tumor and body-chemistry requirements to join.
Hangzhou, ZhejiangAges 18 years+ - NCT05422794RecruitingPhase 1
Adding a new drug plus pembrolizumab to standard chemo for TNBC
This trial studies whether adding a new anti-cancer drug (ZEN-3694) and the immunotherapy drug pembrolizumab to standard chemotherapy (nab-paclitaxel) can work better for advanced triple-negative breast cancer. It’s testing safety first (Phase 1) and, for some patients, how well the treatment controls the cancer.
Boston, MassachusettsAges 18 years+ - NCT05447702RecruitingPhase 2
Testes pre-surgery treatment for triple-negative breast cancer
This trial studies giving camrelizumab plus apatinib and chemotherapy before surgery for triple-negative breast cancer. The goal is to shrink the tumor and improve outcomes by testing a combination of immune and targeted medicines along with chemotherapy.
Chengdu, SichuanAges 18–75 - NCT05451784RecruitingPhase 1/Phase 2
PD-1 TIL therapy for advanced triple-negative breast cancer
This study tests an immune-cell treatment made from your tumor tissue. It aims to help people with advanced or metastatic triple-negative breast cancer by collecting PD-1–positive immune cells and giving them back after treatment.
BarcelonaAges 18 years+ - NCT05475678RecruitingPhase 2
Camrelizumab plus chemo before surgery for triple-negative breast cancer
This Phase 2 trial tests adding camrelizumab (an immune therapy) to standard chemotherapy before surgery for people with triple-negative breast cancer that has not spread. It aims to improve how much the tumor shrinks before and around the time of surgery.
Zhengzhou, HenanAges 18–70 - NCT05485766RecruitingPhase 2
Pembrolizumab with cancer medicines for BRCA-mutated triple negative breast cancer
This Phase 2 trial studies a treatment plan given before surgery (neoadjuvant) and after surgery (adjuvant) for people with BRCA1/2-mutated triple negative breast cancer that has not spread. It aims to improve how well the cancer responds and how long people stay cancer-free.
Gifu, GifuAges 18 years+ - NCT05490472RecruitingPhase 1/Phase 2
Study drug for advanced solid tumors that stopped responding
This early study tests a new medicine (JAB-2485) in adults with advanced solid tumors (cancers that have spread or grown locally). You may join to see if it can shrink tumors or control the disease when other treatments haven’t worked or weren’t tolerated.
Detroit, MichiganAges 18 years+ - NCT05491226RecruitingPhase 2
Pembrolizumab plus radiation and myeloid-targeting for high-risk breast cancer
This trial studies whether adding pembrolizumab (an immune “unlocking” drug) to radiation and another treatment that targets certain immune cells can improve outcomes for women with high-risk, early-stage triple negative breast cancer. You may be considered if your cancer has signs that it may respond less to immunotherapy on its own.
Los Angeles, CaliforniaAges 18 years+ - NCT05491083RecruitingPhase 1/Phase 2
Pembrolizumab plus ADG106 for advanced triple-negative breast cancer
This early-phase study tests pembrolizumab (an immune therapy) combined with ADG106 in people with advanced solid tumors, and specifically triple-negative breast cancer. It looks at whether the treatment can shrink tumors and improve outcomes for cancers that are progressing despite prior therapy.
SingaporeAges 21–99 - NCT05492682RecruitingPhase 1
First-in-human treatment for cancer using a drug injected into tumors
This Phase 1 trial tests PeptiCRAd-1, a treatment injected into a tumor, to see how safe it is and whether it can shrink cancers. It studies people whose cancer has come back or can’t be treated with standard options.
FrankfurtAges 18 years+ - NCT05504707RecruitingPhase 1
Study drug for early-stage, HER2-negative, low-risk hormone breast cancer
This Phase 1 trial tests a new study drug called DC1 given before standard breast cancer treatments. It focuses on people with HER2-negative breast cancer that is “hormone negative” or “hormone low,” aiming to see if the treatment is safe and whether it may work before surgery or other local therapy.
Tampa, FloridaAges 18 years+ - NCT05528133RecruitingPhase 2
Personalized radiation based on tumor genetics in triple-negative breast cancer
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
Clearwater, FloridaAges 18 years+ - NCT05541367Recruiting
ER PET/CT scan test for breast cancer
This trial studies how well an ER PET/CT scan can image breast cancer. It may help doctors see whether a cancer has estrogen receptor (ER) activity, which can guide treatment planning.
Wuhan, HubeiAges 18 years+ - NCT05550415RecruitingPhase 2
Simvastatin with chemotherapy for triple-negative breast cancer
This trial studies whether adding simvastatin (a cholesterol medicine) can slow or change how breast cancer spreads in triple-negative breast cancer. It compares outcomes while you receive planned chemotherapy, and you may or may not be taking simvastatin as part of the study treatment.
Jakarta Pusat, DKI JakartaAges 18 years+ - NCT05570253RecruitingPhase 2
SDX-7320 plus eribulin for metastatic triple-negative breast cancer
This Phase 2 study tests whether adding SDX-7320 to eribulin can work better for people with triple-negative metastatic breast cancer. It focuses on patients who have had prior chemotherapy and who also show signs of metabolic imbalance such as higher body weight or higher HbA1c.
Miami, FloridaAges 18 years+ - NCT05579366RecruitingPhase 1/Phase 2
Study drug for advanced ovarian and other solid cancers
This Phase 1/2 trial studies Rinatabart Sesutecan to treat advanced cancers, with special focus on certain ovarian cancer types. It’s meant for people whose cancer has come back or has not responded to prior treatments.
Phoenix, ArizonaAges 18 years+ - NCT05582499RecruitingPhase 2
Neoadjuvant treatment study for certain breast cancers
This Phase 2 study tests a “precision platform” approach—treatment before surgery—based on specific test results from your breast tumor. It may help determine whether the treatment plan works better for people with particular breast cancer subtypes and healthy organ function.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT05582538RecruitingPhase 2
Ceralasertib plus immunotherapy for advanced triple-negative breast cancer
This Phase 2 trial tests whether a drug called ceralasertib can help the immune system work better, followed by durvalumab plus nab-paclitaxel. It is for people with advanced triple-negative breast cancer whose cancer returned after earlier treatment, including chemotherapy and immune therapy.
Novara, NovaraAges 18 years+ - NCT05627960RecruitingPhase 1
Testing an antibody drug for advanced solid cancers
This Phase 1 study tests AG01, an antibody that targets a cancer protein called GP88, in people with advanced solid tumors. The goal is to find safe doses and learn whether it can help certain cancers.
Baltimore, MarylandAges 18 years+ - NCT05660083RecruitingPhase 2
Study of alpelisib plus iNOS inhibitor with nab-paclitaxel
This Phase 2 trial tests whether a combination of medicines can shrink and control HER2-negative metaplastic breast cancer that cannot be removed with surgery (locally advanced) or has spread (metastatic). It may help people whose cancer has specific lab/pathology features, and it also checks safety and how well the treatment works in the body.
Bethesda, MarylandAges 18 years+ - NCT05677802Recruiting
Stress-reduction program for newly diagnosed triple-negative breast cancer
This study tests whether a structured stress-reduction program can help people with newly diagnosed triple-negative breast cancer (stages I–III). The goal is to see if the program is practical and beneficial for patients during treatment.
Cleveland, OhioAges 18 years+ - NCT05722795Recruiting
Imatinib to change triple-negative breast cancer to ER-positive
This trial studies whether imatinib (a pill medicine) can “convert” triple-negative breast cancer into an ER-positive type, which may change how the cancer behaves. If the conversion happens, it could open the door to more treatment options in the future.
GothenburgAges 18 years+ - NCT05736367Recruiting
Study tumor metabolism in certain types of breast cancer surgery
This study looks at how breast cancer cells use energy and nutrients in hormone-receptor positive, HER2-negative tumors during planned surgery. It may help researchers understand the cancer better by comparing tumor tissue with nearby normal tissue.
New Brunswick, New JerseyAges 18 years+ - NCT05741164RecruitingPhase 2
Propranolol plus pembrolizumab for hard-to-treat breast cancer
This Phase 2 trial studies whether adding propranolol to pembrolizumab can “re-sensitize” tumors and slow cancer in triple-negative breast cancer that no longer responds to checkpoint immunotherapy. It may help some people whose cancer has grown despite prior pembrolizumab and chemotherapy.
Atlanta, GeorgiaAges 18 years+
Hear when a new Breast Cancer Triple Negative trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast cancer triple negative?
- Yes. Clin2 currently lists 431 recruiting breast cancer triple negative studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast cancer triple negative trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast cancer triple negative trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Breast Cancer (Triple Negative Breast Cancer (TNBC))
- Triple Negative Breast Cancer
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Metastatic Triple-negative Breast Cancer
- Advanced Triple Negative Breast Cancer
- Triple Negative Breast Cancer (TNBC), Early Setting
- HER2-negative Breast Cancer
- Triple Negative Breast Neoplasms
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.